<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505219</url>
  </required_header>
  <id_info>
    <org_study_id>ABI 55-0705-1</org_study_id>
    <nct_id>NCT00505219</nct_id>
  </id_info>
  <brief_title>Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head</brief_title>
  <acronym>ON-CORE</acronym>
  <official_title>Multi-center Clinical Trial of the Application of Ixmyelocel-T in the Treatment of Osteonecrosis of the Femoral Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vericel Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vericel Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Ixmyelocel-T grafting with demineralized bone&#xD;
      matrix bound in autologous plasma after core decompression surgery is superior to core&#xD;
      decompression with demineralized bone matrix bound in autologous plasma in preventing&#xD;
      progression of osteonecrosis to a more severe disease stage (Stage II to III or higher) from&#xD;
      the time of surgery until 24 months later, in patients with University of Pennsylvania&#xD;
      (UPenn) Stage IIB or C disease at diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an event-driven, multi-center, prospective, independent observer-blinded,&#xD;
      controlled, randomized Phase III clinical trial enrolling patients diagnosed with University&#xD;
      of Pennsylvania (Steinberg) Classification Stage IIB or C osteonecrosis of the femoral head.&#xD;
&#xD;
        -  The first patient group is the Treatment Group and will receive core decompression and&#xD;
           treatment with BRCs and demineralized bone matrix bound in autologous plasma, and&#xD;
&#xD;
        -  The second patient group is the Control Group and will receive core decompression and&#xD;
           demineralized bone matrix bound in autologous plasma, without any BRCs.&#xD;
&#xD;
        -  Enrollment: With an anticipated drop-out rate of 10% in up to twenty (20) sites, a total&#xD;
           of approximately 135 patients will be enrolled and randomized to obtain 120 evaluable&#xD;
           patients (75 for the TRC treatment group and 45 for the Control treatment group).&#xD;
&#xD;
        -  Primary endpoint: The percentage of patients progressing to a more severe UPenn disease&#xD;
           stage (Stage II to III or higher) between 0 and 24 months will be the primary efficacy&#xD;
           variable to demonstrate TRC therapy is superior to Control therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression of patients with UPenn Stage IIB or IIC disease to a more severe stage based on all available x-ray and MRI imaging. Patients who have a definitive procedure but do not have a valid assessment will be considered to have progressed.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (in months)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteonecrosis volume measured by MRI</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain and quality of life questionnaires</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Osteonecrosis</condition>
  <arm_group>
    <arm_group_label>Ixmyelocel-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Core decompression &amp; treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ixmyelocel-T</intervention_name>
    <description>Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.</description>
    <arm_group_label>Ixmyelocel-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care Only</intervention_name>
    <description>Core decompression of the femoral head to remove necrotic tissue</description>
    <arm_group_label>Standard of Care Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  UPenn (Steinberg) classification of osteonecrosis, inclusive of Stages IIB and IIC.&#xD;
             Diagnosis will be based on magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Modified index of necrotic extent &lt; 40&#xD;
&#xD;
          -  Idiopathic and non-idiopathic osteonecrosis.&#xD;
&#xD;
          -  No infection in affected bones at the time of surgery.&#xD;
&#xD;
          -  Patient competent to give informed consent.&#xD;
&#xD;
          -  Normal organ and marrow function defined as:&#xD;
&#xD;
               -  Leukocytes ≥ 3000/µL;&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1500/µL;&#xD;
&#xD;
               -  Platelets ≥ 140,000/µL;&#xD;
&#xD;
               -  Serum AST (SGOT)/ALT (SGPT) &lt; 2.5 X institutional standard range;&#xD;
&#xD;
               -  Serum creatinine within normal limits, based on clinical laboratory normal range.&#xD;
&#xD;
          -  Female patients not pregnant or lactating.&#xD;
&#xD;
          -  Patients with a history of corticosteroids or on active therapy, will only be eligible&#xD;
             for enrollment if corticosteroid use is suspended for 1 month prior and 6 months after&#xD;
             cell therapy and surgery.&#xD;
&#xD;
          -  Patients who have been treated with oral bisphosphonates are eligible for the trial if&#xD;
             treatment was stopped at least 6 months prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stages IA, IB, IC, IIA, IIIA or more severe femoral head osteonecrosis, primarily&#xD;
             based on diagnosis by MRI.&#xD;
&#xD;
          -  Flattening of the femur head (UPenn Stage IV) or articular cartilage collapse at the&#xD;
             time of core decompression surgery.&#xD;
&#xD;
          -  Septic arthritis; stress fracture, or non-osteonecrosis metabolic bone diseases (e.g.,&#xD;
             Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, fibrous&#xD;
             dysplasia [monostotic, polyostotic McCune-Albright syndrome] and osteopetrosis).&#xD;
&#xD;
          -  Any active bisphosphonate treatment or any history of intravenous (IV) treatment&#xD;
&#xD;
          -  HIV, syphilis, positive at time of screening.&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection at the time of screening&#xD;
&#xD;
          -  Known allergies to protein products (horse or bovine serum, or porcine trypsin).&#xD;
&#xD;
          -  Patients who will require continuous, systemic, high dose corticosteroid therapy (more&#xD;
             than 7.5 mg/day) within 6 months after surgery.&#xD;
&#xD;
          -  Patients in active treatment for cancer or blood dyscrasia, or have received&#xD;
             chemotherapy, radiotherapy or immunotherapy in the past 2 years.&#xD;
&#xD;
          -  Immunodeficiency diseases.&#xD;
&#xD;
          -  Participation in another clinical study in the past 30 days or concurrent&#xD;
             participation in another clinical trial.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 5 oz [150 mL]&#xD;
             of wine or 12 oz [360 mL] of beer or 1.5 oz [45 mL] of hard liquor) within 6 months of&#xD;
             screening and/or history of illicit drug use.&#xD;
&#xD;
          -  MRI-incompatible internal devices (pacemakers, aneurysm clips, etc)&#xD;
&#xD;
          -  Body mass index (BMI) of 40 Kg/m2 or greater&#xD;
&#xD;
          -  Patients unable to tolerate general anesthesia defined as an American Society of&#xD;
             Anesthesiologists (ASA) criteria of &gt; 2&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus (HbA1C &gt; 8%), or with peripheral&#xD;
             neuropathy, or known concomitant vascular problems.&#xD;
&#xD;
          -  Patients receiving treatment with hematopoietic growth factors or anti-vasculogenesis&#xD;
             or anti-angiogenesis treatment&#xD;
&#xD;
          -  Traumatic osteonecrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Hungerford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Department of Orthopaedic Surgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 29, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 1, 2016</disposition_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteonecrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Legg-Calve-Perthes Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

